Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering a novel therapeutic approach known as immuno-neurology. The company leverages the body’s innate immune system to develop treatments for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). Alector’s groundbreaking research focuses on counteracting brain pathologies by restoring healthy immune function.
The company’s pipeline includes several promising product candidates like AL001 (latozinemab), AL002, AL003, and AL101. Among these, latozinemab and AL101 are being co-developed in collaboration with global biopharmaceutical giant GSK. Latozinemab, a progranulin-elevating monoclonal antibody, is currently in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN and has received FDA Breakthrough Therapy and Fast Track designations.
AL002, in collaboration with AbbVie, is a TREM2-activating antibody undergoing a Phase 2 INVOKE-2 trial to assess its efficacy in early Alzheimer's disease. The company recently completed enrollment for INVOKE-2, with a data readout expected in the fourth quarter of 2024. AL101, another progranulin-elevating candidate, has initiated the PROGRESS-AD Phase 2 trial to treat early Alzheimer's disease.
Alector’s innovative Alector Brain Carrier (ABC) technology aims to enhance drug delivery across the blood-brain barrier, further strengthening their therapeutic pipeline. The company’s financial health is robust, with $620.0 million in cash, cash equivalents, and investments as of January 2024. This financial buffer is anticipated to fund operations through 2026, ensuring continued progress in their clinical programs.
For ongoing updates and detailed information, visit their official website at www.alector.com.
Alector, Inc. (NASDAQ: ALEC) has presented preclinical data for its first-in-class immuno-oncology therapy, AL009, at the Society for Immunotherapy of Cancer’s annual meeting. AL009 targets multiple Siglec receptors to enhance immune response against solid tumors. Preclinical studies indicate that AL009 significantly improves T cell function (up to 100-fold) and demonstrates efficacy in reducing tumor growth in resistant tumor models. Alector plans to commence first-in-human clinical trials for AL009 in 2022, aiming to impact a range of solid tumor types and mitigate immune suppression by tumors.
Alector (Nasdaq: ALEC) presented data from its AL003 and AL101 clinical programs at the 14th CTAD conference in November 2021. The company aims to leverage immune system mechanisms to combat neurodegenerative diseases. AL003 is in Phase 1 trials, showing a favorable safety profile, while AL101 is also in Phase 1 and is designed to elevate progranulin levels. Both candidates are progressing into further studies, with AL003 set for a Phase 2 trial in late 2022. The conference presentations include additional data on Alector's pipeline, showcasing advances in immuno-neurology therapies.
Alector, a clinical-stage biotechnology company based in South San Francisco, is announcing its participation in the Stifel 2021 Virtual Healthcare Conference. CEO Arnon Rosenthal will engage in a fireside chat on November 15, 2021, at 2:00 p.m. ET. A live webcast of the session will be accessible on Alector's Investors section. Alector specializes in immuno-neurology, focusing on innovative treatments for neurodegenerative diseases, with ongoing developments targeting conditions such as frontotemporal dementia and Alzheimer's disease. A replay of the event will be available for 90 days.
Alector, Inc. (Nasdaq: ALEC) reported significant progress in its third quarter 2021 results, including a net income of $126.6 million, or $1.56 per share, compared to a net loss of $52.7 million in Q3 2020. Collaboration revenue surged to $182.4 million, driven primarily by a $500 million upfront payment from GSK for co-developing neurodegenerative disease treatments. The company has initiated a Phase 2 trial of AL001 in ALS patients and received orphan drug designation for frontotemporal dementia.
Alector (Nasdaq: ALEC) will present at two major conferences: the 14th Clinical Trials on Alzheimer's Disease (CTAD) from November 9-12, 2021, and the Society for Immunotherapy of Cancer's (SITC) annual meeting from November 12-14, 2021. Data shared will include results from the Phase 2 INFRONT-2 study of AL001 for frontotemporal dementia and Phase 1 studies of AL003. Alector will also update on AL009 at SITC. An analyst and investor conference call is set for November 12, 2021, at 4:00 p.m. ET to discuss these findings.
Alector, Inc. (Nasdaq: ALEC) has appointed Dr. Elizabeth (Betsy) A. Garofalo to its Board of Directors. With over 25 years in biopharmaceuticals, Dr. Garofalo brings extensive experience in global clinical development, especially in neurology. She has previously held significant roles at Novartis and Pfizer. Dr. Garofalo emphasized Alector's potential in neurology, particularly with its innovative immuno-neurology approach targeting degenerative diseases like Alzheimer’s and ALS. Her leadership is expected to enhance the company’s clinical programs as they advance into later-stage trials.
Alector (ALEC) has initiated a Phase 2 clinical trial for AL001 in patients with C9orf72-associated amyotrophic lateral sclerosis (ALS). This randomized, placebo-controlled study will involve approximately 45 participants who will receive AL001 or placebo intravenously every four weeks. The trial aims to evaluate safety, tolerability, and pharmacodynamics, focusing on progranulin levels. AL001 could potentially elevate brain progranulin levels, offering a neuroprotective effect against TDP-43 aggregation, which is linked to ALS pathology. This study represents a significant step towards developing targeted ALS treatments.
Alector, Inc. (Nasdaq: ALEC) announces organizational changes with Shehnaaz Suliman and Robert Paul stepping down as President and Chief Medical Officer, respectively. Sam Jackson appointed as interim Chief Medical Officer. Suliman and Paul will assist during the transition until year-end. Alector has six clinical studies ongoing for four candidates and plans to introduce new treatments in 2022. The CEO expresses gratitude for their contributions, stating the company is well-positioned for future growth in immuno-neurology.
Alector, a clinical-stage biotechnology company pioneering immuno-neurology, has announced participation in several upcoming virtual investor conferences. Key events include:
- Citi’s 16th Annual Biopharma Virtual Conference: Sept 8 at 11:35 a.m. ET and Sept 9 at 1:25 p.m. ET.
- Wells Fargo Virtual Healthcare Conference: Sept 10 at 2:00 p.m. ET.
- Morgan Stanley 19th Annual Global Healthcare Conference: Sept 13 at 11:45 a.m. ET.
Webcasts will be available on the Alector website, with replays for 30 days.
Alector (NASDAQ: ALEC) reported its Q2 2021 financial results, highlighting collaboration revenue of $6.6 million, up from $3.2 million year-over-year. The company continues to advance its AL001 program in frontotemporal dementia (FTD-GRN), presenting twelve-month data showing a 47% clinical progression slowdown. Alector and GSK established a global partnership, granting Alector $700 million upfront and up to $1.5 billion in potential milestones. As of June 30, 2021, cash and investments totaled $319.6 million, sufficient for operations into mid-2024.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
What is Alector, Inc. known for?
What are the main product candidates in Alector's pipeline?
What recent achievements has Alector accomplished?
Who are Alector's key collaborators?
What is the focus of Alector's immuno-neurology approach?
When is the data readout for the INVOKE-2 trial expected?
What is the Alector Brain Carrier (ABC) technology?
What financial condition is Alector currently in?
What is the significance of the FDA Breakthrough Therapy Designation for latozinemab?
Where can more information about Alector be found?
